People | January 17, 2022
SeQuent Scientific appoints Rajaram Narayanan as MD & CEO
Narayanan to lead SeQuent through next phase of consolidation and growth
Narayanan to lead SeQuent through next phase of consolidation and growth
The global multi-center phase-II clinical trial will be a 36-week, multi-center, randomized, double-blind, placebo-controlled trial, followed by a 36-week open-label extension period
The new collaboration focuses on a class of proteins called transcription factors, which control gene expression and can regulate important cellular processes including cell growth and survival
The last date to apply for this program is 18th January 2022
This test analyses samples in VTM directly without the need for RNA extraction step
KardiaMobile is the first personal ECG to be recommended by NICE for use within the National Health Service (NHS) in England and Wales
The stability is led by healthy demand in the domestic and emerging markets
The study will be published on the pre-print server, medRXiv, shortly
Four-year research collaboration combines Pfizer’s deep experience in global drug development, including programs utilizing messenger RNA (mRNA), lipid nanoparticles (LNP), and gene therapy, with Beam’s leadership in base editing and mRNA/LNP delivery technologies
Acquisition adds Adaptate’s novel antibody-based ?? T-cell engager platform to Takeda’s Immuno-oncology portfolio built around the Innate Immune System
Subscribe To Our Newsletter & Stay Updated
